
## Fumitaka Kikkawa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5827442/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of Indirect Nonequilibrium Atmospheric Pressure Plasma on Anti-Proliferative Activity against Chronic Chemo-Resistant Ovarian Cancer Cells In Vitro and In Vivo. PLoS ONE, 2013, 8, e81576.	2.5	335
2	Plasma-Activated Medium Selectively Kills Glioblastoma Brain Tumor Cells by Down-Regulating a Survival Signaling Molecule, AKT Kinase. Plasma Medicine, 2011, 1, 265-277.	0.6	284
3	Cell survival of glioblastoma grown in medium containing hydrogen peroxide and/or nitrite, or in plasma-activated medium. Archives of Biochemistry and Biophysics, 2016, 605, 102-108.	3.0	203
4	Non-thermal atmospheric pressure plasma activates lactate in Ringer's solution for anti-tumor effects. Scientific Reports, 2016, 6, 36282.	3.3	167
5	Endometriosis and cancer. Free Radical Biology and Medicine, 2019, 133, 186-192.	2.9	94
6	Plasma Medical Science for Cancer Therapy: Toward Cancer Therapy Using Nonthermal Atmospheric Pressure Plasma. IEEE Transactions on Plasma Science, 2014, 42, 3760-3764.	1.3	91
7	Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. Journal of Surgical Oncology, 2006, 94, 138-143.	1.7	83
8	Cell survival and proliferation signaling pathways are downregulated by plasma-activated medium in glioblastoma brain tumor cells. Plasma Medicine, 2012, 2, 207-220.	0.6	76
9	Fertility-sparing surgery in patients with clear-cell carcinoma of the ovary: Is it possible?. Human Reproduction, 2011, 26, 3297-3302.	0.9	55
10	Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types. Gynecologic Oncology, 2011, 123, 474-478.	1.4	51
11	Plasma-activated medium suppresses choroidal neovascularization in mice: a new therapeutic concept for age-related macular degeneration. Scientific Reports, 2015, 5, 7705.	3.3	47
12	PAI-1 secreted from metastatic ovarian cancer cells triggers the tumor-promoting role of the mesothelium in a feedback loop to accelerate peritoneal dissemination. Cancer Letters, 2019, 442, 181-192.	7.2	41
13	Inhibition of ZEB1 leads to inversion of metastatic characteristics and restoration of paclitaxel sensitivity of chronic chemoresistant ovarian carcinoma cells. Oncotarget, 2017, 8, 99482-99494.	1.8	36
14	Adjuvant Chemotherapy for Stage I Ovarian Clear Cell Carcinoma: Is it Necessary for Stage IA?. International Journal of Gynecological Cancer, 2012, 22, 1143-1149.	2.5	33
15	Non-thermal plasma-activated medium modified metabolomic profiles in the glycolysis of U251SP glioblastoma. Archives of Biochemistry and Biophysics, 2019, 662, 83-92.	3.0	33
16	KIF20A expression as a prognostic indicator and its possible involvement in the proliferation of ovarian clearâ€cell carcinoma cells. Oncology Reports, 2018, 40, 195-205.	2.6	29
17	A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. International Journal of Clinical Oncology, 2014, 19, 921-927.	2.2	22
18	Prognostic factors and effects of fertility-sparing surgery in women of reproductive age with ovarian clear-cell carcinoma: a propensity score analysis. Journal of Gynecologic Oncology, 2019, 30, e102.	2.2	21

**ΓUMITAKAKIKKAWA** 

#	Article	IF	CITATIONS
19	A post-recurrence survival‑predicting indicator for cervical cancer from the analysis of 165Ã <sup>-</sup> ¿½patients who developed recurrence. Molecular and Clinical Oncology, 2018, 8, 281-285.	1.0	20
20	Non-thermal plasma–activated lactate solution kills U251SP glioblastoma cells in an innate reductive manner with altered metabolism. Archives of Biochemistry and Biophysics, 2020, 688, 108414.	3.0	20
21	A novel mechanism of neovascularization in peritoneal dissemination via cancer-associated mesothelial cells affected by TGF-β derived from ovarian cancer. Oncology Reports, 2017, 39, 193-200.	2.6	18
22	Adjusted multiple gases in the plasma flow induce differential antitumor potentials of plasmaâ€activated solutions. Plasma Processes and Polymers, 2020, 17, 1900259.	3.0	17
23	The possible existence of occult metastasis in patients with ovarian clear-cell carcinoma who underwent complete resection without any residual tumours. Oncotarget, 2018, 9, 6298-6307.	1.8	17
24	Prognostic value of neutrophil-to-lymphocyte ratio in early-stage ovarian clear-cell carcinoma. Journal of Gynecologic Oncology, 2019, 30, e85.	2.2	15
25	Survival impact of capsule status in stage I ovarian mucinous carcinoma—A mulicentric retrospective study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2019, 234, 131-136.	1.1	13
26	The upregulated expression of vascular endothelial growth factor in surgically treated patients with recurrent/radioresistant cervical cancer of the uterus. Oncology Letters, 2018, 16, 515-521.	1.8	11
27	Fertility-sparing surgery and oncologic outcome among patients with early-stage ovarian cancer ~propensity score- matched analysis~. BMC Cancer, 2019, 19, 1235.	2.6	11
28	The Preoperative Prognostic Nutritional Index for the Prediction of Outcomes in Patients with Early-Stage Ovarian Clear Cell Carcinoma. Scientific Reports, 2020, 10, 7135.	3.3	11
29	Synthesis of calcium oxalate crystals in culture medium irradiated with non-equilibrium atmospheric-pressure plasma. Applied Physics Express, 2016, 9, 096201.	2.4	10
30	The impact of systematic retroperitoneal lymphadenectomy on long-term oncologic outcome of women with advanced ovarian clear-cell carcinoma. Journal of Gynecologic Oncology, 2020, 31, e47.	2.2	10
31	Impact of positive ZEB1 expression in patients with epithelial ovarian carcinoma as an oncologic outcome-predicting indicator. Oncology Letters, 2017, 14, 4287-4293.	1.8	9
32	Oncologic and reproductive outcomes of cystectomy as a fertility-sparing treatment for early-stage epithelial ovarian cancer. International Journal of Clinical Oncology, 2019, 24, 857-862.	2.2	9
33	Comparison of long-term oncologic outcomes between metastatic ovarian carcinoma originating from gastrointestinal organs and advanced mucinous ovarian carcinoma. International Journal of Clinical Oncology, 2019, 24, 950-956.	2.2	8
34	Amniotic lamellar body count: predicting and distinguishing neonatal respiratory complications in twin pregnancies. Clinica Chimica Acta, 2015, 441, 75-78.	1.1	7
35	Expression of connective tissue growth factor as a prognostic indicator and its possible involvement in the aggressive properties of epithelial ovarian carcinoma. Oncology Reports, 2019, 42, 2323-2332.	2.6	7
36	Secondary cytoreductive surgery potentially improves the oncological outcomes of patients with recurrent uterine sarcomas. Molecular and Clinical Oncology, 2018, 8, 499-503.	1.0	6

#	Article	IF	CITATIONS
37	Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 181, 305-310.	1.1	4
38	Crystallization of calcium oxalate dihydrate in a buffered calcium-containing glucose solution by irradiation with non-equilibrium atmospheric pressure plasma. Journal of Applied Physics, 2017, 122, 143301.	2.5	4
39	The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer. Journal of Obstetrics and Gynaecology Research, 2019, 45, 2435-2439.	1.3	4
40	Regulation of Prolactin Gene Expression During Early Pregnancy in Rats Endocrinologia Japonica, 1989, 36, 395-401.	0.5	3
41	Adjuvant taxane plus platinum chemotherapy for stage I ovarian clear cell carcinoma with complete surgical staging: are more than three cycles necessary?. International Journal of Clinical Oncology, 2022, 27, 609-618.	2.2	2
42	Establishment and characterization of cell lines from human endometrial epithelial and mesenchymal cells from patients with endometriosis. F&S Science, 2020, 1, 195-205.	0.9	0